Alector, Inc. (ALEC): Total Assets
$293.24M
As of 2025-12-31
$202.85M
As of 2026-06-30
-28.1%
3-year compound annual growth
-9.7%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $293.24M | -37.4% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $468.30M | -24.7% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $621.83M | -21.1% | 2025-02-26, Balance as of period end |
| 2022-12-31 | $787.65M | -3.3% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $814.66M | +66.9% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $488.25M | +15.7% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $421.91M | +36.8% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $308.36M | n/a | 2020-03-24, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Alector, Inc. (ALEC) | 2025-12-31 | $293.24M | -37.4% |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $305.88M | +42.1% |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $221.10M | -31.9% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $130.40M | n/m |
| Relay Therapeutics, Inc. (RLAY) | 2025-12-31 | $621.33M | -28.7% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $364.98M | +292.7% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $112.58M | -0.6% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $154.42M | +13.2% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $290.46M | +98.3% |
Compare ALEC, LENZ, MGX, PTHS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗